mark nash
Novartis Institutes for BioMedical Research
Cambridge, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
Novartis Institutes for BioMedical Research
Cambridge, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
University of Kansas Medical Center
Kansas City, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
Department of Hematology, Fifth Medical Center of the PLA General Hospital
Beijing, China
Review Editor
Gastrointestinal and Hepatic Pharmacology
Harbin Medical University
Harbin, China
Review Editor
Gastrointestinal and Hepatic Pharmacology
University at Buffalo
Buffalo, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
Institute of Health and Sport, College of Health and Biomedicine, Victoria University
Melbourne, Australia
Review Editor
Gastrointestinal and Hepatic Pharmacology
University of Galway
Galway, Ireland
Review Editor
Gastrointestinal and Hepatic Pharmacology
The Catholic University of America, Rome Campus
Rome, Italy
Review Editor
Gastrointestinal and Hepatic Pharmacology
Biodonostia Health Research Institute (IIS Biodonostia)
San Sebastian, Spain
Review Editor
Gastrointestinal and Hepatic Pharmacology
Regional University of Cariri
Crato, Brazil
Review Editor
Gastrointestinal and Hepatic Pharmacology
Oregon Health and Science University
Portland, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center
Oklahoma City, United States
Review Editor
Gastrointestinal and Hepatic Pharmacology
Rey Juan Carlos University
MĂłstoles, Spain
Review Editor
Gastrointestinal and Hepatic Pharmacology
University of Tabuk
Tabuk, Saudi Arabia
Review Editor
Gastrointestinal and Hepatic Pharmacology
INI, Istituto Neurotraumatologico Italiano
Roma, Italy
Review Editor
Gastrointestinal and Hepatic Pharmacology
University of Szeged
Szeged, Hungary
Review Editor
Gastrointestinal and Hepatic Pharmacology